Comparison of the Radiosensitizing Effect of ATR, ATM and DNA-PK Kinase Inhibitors on Cervical Carcinoma Cells

J Vávrová1, L Zárybnická1, P Jošt2

  • 1Department of Radiobiology, Faculty of Military Health Sciences, Hradec Králové, University of Defence Brno, Czech Republic.

Folia Biologica
|September 20, 2016
PubMed

Insights

This study compared ATM, ATR, and DNA-PK inhibitors for radiosensitizing cervical cancer cells. ATR inhibitor VE-821 showed early radiosensitizing effects by causing mitotic catastrophe, while ATM and DNA-PK inhibitors had delayed effects.

Area of Science:

  • Oncology
  • Cell Biology
  • Radiation Oncology

Background:

  • Phosphatidylinositol-3-kinase-related kinases (PIKKs) play crucial roles in DNA damage response.
  • Targeting PIKKs is a strategy to enhance cancer cell radiosensitivity.

Purpose of the Study:

  • To compare the radiosensitizing effects of ATM, ATR, and DNA-PK inhibitors on cervical carcinoma cells.
  • To investigate the impact of these inhibitors on cell cycle progression and DNA repair pathways.

Main Methods:

  • HeLa cervical carcinoma cells were treated with ATM (KU55933), ATR (VE-821), and DNA-PK (NU7441) inhibitors.
  • Cells were irradiated at doses of 8 Gy and 15 Gy.
  • Cell cycle distribution, Chk1/Chk2 phosphorylation, and colony-forming ability were assessed.
  • Real-time cell proliferation was monitored using the xCELLigence system.

Main Results:

  • VE-821 (ATR inhibitor) promoted G2/M arrest and mitotic catastrophe, leading to radiosensitization.
  • KU55933 (ATM inhibitor) and NU7441 (DNA-PK inhibitor) enhanced G2 arrest but showed delayed radiosensitizing effects.
  • ATR inhibition resulted in early radiosensitization, while ATM and DNA-PK inhibition effects were observed at 72 hours post-irradiation.

Conclusions:

  • ATR inhibition (VE-821) offers a promising strategy for early radiosensitization in cervical cancer.
  • Differential timing of radiosensitization exists between ATR, ATM, and DNA-PK inhibitors.
  • Combination therapies targeting PIKKs warrant further investigation for improved cervical cancer treatment.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.3K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
45.2K